Estradiol: a hormone with diverse and contradictory neuroprotective actions by Wise, Phyllis M. et al.
n 2002 we contributed an article to Dialogues
in Clinical Neuroscience which discussed the neuropro-
tective actions of estrogens.
1 In this review we build on
the understanding we had at that point, and will discuss
the importance of the accumulating data that point to
the complexities of estrogen action. Clearly, many fac-
tors, including the type of estrogen used, the dose and
route of administration, and the age and previous hor-
monal and health status of the women being treated,
must be taken into consideration when designing clini-
cal studies and when interpreting results.
Women usually undergo the menopausal transition when
they are about 51 years of age. This dramatic physiological
change, which may be abrupt or may occur over a period
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The concept that estrogens exert important neuroprotective actions has gained considerable attention during the past
decade. Numerous studies have provided a deep understanding of the seemingly contradictory actions of estrogens.
We realize more than ever that the effects of estrogens (with and without simultaneous or sequential progestins) are
diverse and sometimes opposite, depending on the use of different estrogenic and progestinic compounds, on dif-
ferent delivery routes, on different concentrations, on treatment sequence, and on the age and health status of the
women who receive hormone therapy. During the past few years, we have gained an increasing appreciation of the
impact of estrogens on the immune system and on inflammation. In addition, we have learned that estrogens cannot
only protect against cell death, but can also stimulate the birth of new neurons. Here we posit the concept that estro-
gen’s modulation of the immune status may be the basic mechanism that underlies its ability to protect against neu-
rodegeneration and its powerful neuroregenerative actions. We hope that this update will encourage even richer dia-
logues between basic and clinical scientists to ensure that future clinical studies fully consider the information that can
be derived from basic science studies. Only then will we have a better understanding of the impact of hormones on
the menopausal and postmenopausal period in a woman’s life.
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PAGES_10_AG_019_BA.qxd:DCNS#42  30/08/09  1:25  Page 297of a few years, is marked by a decline in ovarian hormone
secretion and cessation of reproductive fertility. The post-
menopausal period is often associated with vaginal dry-
ness, urinary symptoms, osteoporosis, and a panel of neu-
rological manifestations such as hot flushes, and greater
instances of sleep disturbance, emotional instability, cere-
brovascular stroke, and Alzheimer's disease. Over the past
century the average life expectancy in the United States
has increased to over 80 years, while the age of menopause
has remained fixed at age 51. Thus, today, more than ever
before, a greater number of women and a larger propor-
tion of women are destined to spend over three decades
of their lives in a hypoestrogenic state. This makes it imper-
ative that we understand the intricacies of estrogen action,
when it is protective, and when it increases risk.
Estrogens and progestins
Estradiol and progesterone belong to a family of steroid
hormones with complex actions. Estradiol-17β (E2), the
predominant and most biologically active estrogen, is an
18 carbon (C-18) steroid with an aromatic A-ring. It is
synthesized mainly by the ovary; however, other organs
and tissues, including adipose tissue, the brain (neurons,
astrocytes, and microglia), cells of the immune system, and
bone, are thought to produce it as well. Progesterone is
a C-21 steroid hormone, which is not only an active hor-
mone in and of itself, but is also a precursor to estrogens.
In addition to the estrogens and progestins produced in
human tissues, a wide variety of estrogenic and progesto-
genic compounds are synthesized in other species or are
pharmacologically manufactured through pathways that
have been developed by researchers and have been used
widely by the pharmaceutical industry. When used in hor-
mone therapy for postmenopausal women, the actions of
these different compounds are diverse, complex, and
sometimes contradictory. Their effects depend upon the
concentration, whether they are given simultaneously or
sequentially, the route of delivery, and on the age and
health status of the women who receive hormone therapy.
Turgeon et al
2 have provided a detailed review of our cur-
rent understanding of estrogens, progestogens, their
related compounds, agonists, and antagonists. 
Estrogens and stroke
Stroke is the third leading cause of death for middle-
aged and older women and a major health problem that
affects 500 000 Americans each year.
3 Every year
approximately 40 000 more women than men are
affected by stroke.
4 Initially, this gender difference was
thought to be explained by a combination of both the
longer life expectancy of women and the protective roles
of estrogen, since the incidence of stroke increases after
menopause and the risk continues to rise with age.
5
However, this interpretation has been questioned since
recent clinical trials including the Women's Health ini-
tiative (WHI) reported negative impact of estrogen ther-
apy (ET)
4,6-8 and some studies in animal models also sug-
gest that estrogens are not universally protective and can
be deleterious under some circumstances.
9 In an attempt
to reconcile these seemingly contradictory data, our lab
has used animal models to explore the mechanisms of
estrogen’s neuroprotective and neuroregenerative
actions.
Estrogens and stroke: use of animal models
to decipher mechanisms of action
Even the best, well-designed clinical studies cannot ben-
efit from the experimental advantages of many basic sci-
ence studies, since studies performed with experimental
animal models allow replication with adequate numbers
of animals, controls with equivalent genetic backgrounds
and previous exposure to similar environments, well-
controlled environments during the entire study, and
lack of selection or recall bias. Thus, investigators have
developed several animal models to investigate the
pathophysiology and potential treatments for stroke.
Since most cerebrovascular strokes (>70%) in aging
human populations are ischemic, and not hemorrhagic,
we adopted an animal model that reproduces ischemic
infarcts. We have utilized permanent middle cerebral
artery occlusion (MCAO) as a model of permanent
occlusion of the middle cerebral artery, which vascular-
izes the cerebral cortex, the striatum, and the hip-
pocampus, to examine the effects of estrogen in neu-
rodegeneration. Blockade of this artery at its base
results in about a 50% decrease in blood flow and causes
severe metabolic impairment in a core region, called the
“ischemic core” and many neurons in these regions die
by necrosis within hours following injury. In contrast,
regions that surround the ischemic core, the ischemic
penumbra, undergo more moderate metabolic impair-
ment and are potentially salvageable by effective thera-
peutic agents. We have previously demonstrated that E2
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penumbra where E2 protects neurons from delayed pro-
grammed cell death or apoptosis.
10-12
Studies in the early 1990s suggested that estradiol is a neu-
roprotective factor that profoundly attenuates the degree
of ischemic brain injury: i) female gerbils demonstrate less
neuronal pathology than males after ischemia induced by
unilateral carotid artery occlusion; ii) female rats sustain
over 50% less infarction than males and ovariectomized
female rats following ischemia induced by transient occlu-
sion of the middle cerebral artery (MCA); iii) both
ovariectomized females and castrated males that are
treated with estradiol suffer less MCAO-induced injury
than vehicle-treated gonadecetomized controls.
1 Our
work has contributed significantly to the understanding
of the neuroprotective actions of physiological levels of
E2. We have shown that low, physiological levels of E2,
exert profound neuroprotective actions after MCAO.
10-13
We have also demonstrated that E2 effectively reduces
the infarct volume in middle-aged animals, suggesting that
a constellation of factors responsible for mediating E2’s
protective actions is preserved during the initial stages of
aging.
14 Further, we have found that E2 must be adminis-
tered prior to the onset of injury, since acute administra-
tion of E2 at the time of injury does not reduce the extent
of infarction.
15 Collectively, the results of these studies sug-
gest that postmenopausal women who are estrogen-
replaced may suffer a decreased degree of brain injury
following a stroke, compared with their hypoestrogenic
counterparts. However, we must be careful in extrapolat-
ing from rodents to humans until the appropriate clinical
studies are performed.
Estrogen receptor α mediates 
estrogen’s neuroprotective actions
To date, two forms of nuclear estrogen receptor (ER)
have been cloned. Since the discovery of the second
form of ER (ERβ) in 1996, researchers have investigated
the similarities and differences in the distribution and
actions of these two forms of ER. Recently, we found
that ischemic injury upregulates ERα expression in the
cortex of ovariectomized animals without influencing
ERβ expression.
16 Consequently, we hypothesized that
the dramatic re-expression of ERα after stroke injury
mediates E2’s profound neuroprotection against
ischemia.
17,18 Using ERα knockout mice, we found that
the presence of this receptor subtype is a prerequisite for
the ability of E2 to exert protective action against
ischemic injury.
18Taken together, the injured brain seems
to provide signals conveying the need for the reappear-
ance of ERα, which may mediate the ability of E2 to
protect against neuronal apoptosis and possibly reiniti-
ate differentiation of the injured brain.
Anti-inflammatory actions of estrogens
More recently we have begun to appreciate the impor-
tance of inflammation in neurodegeneration and the
role of E2 acting as an anti-inflammatory factor. Many
neurological disorders such as Alzheimer’s disease,
Parkinson’s disease, multiple sclerosis, and cerebrovas-
cular stroke include inflammation processes in the
underlying mechanisms of the disorder.
19 In vivo and in
vitro models of brain injury and neurodegenerative dis-
eases have provided substantial evidence that physio-
logical levels of E2 suppress inflammation through ERα
and ERβ (reviewed in refs 19-22). These studies demon-
strate that estrogens act not only on neurons and astro-
cytes, but also on microglia, the resident macrophages of
the brain (Figure 1). These studies also highlight the
tremendous importance of understanding the crosstalk
between the nervous, endocrine, and immune systems to
fully appreciate the protective role of E2 during neuro-
logical diseases and injury.
19,23
The inflammatory response associated with stroke is
complex, but an accumulating body of evidence clearly
shows that estrogens may directly or indirectly regulate
three components of the inflammatory response: i)
microglial activation; ii) activation of the enzyme;
inducible nitric oxide synthase (iNOS); and iii) the acti-
vation of cytokines/chemokines. These components of
inflammation may interact with each other and are not
mutually exclusive. Microglia become activated in
response to injury, proliferate, migrate to the site of
injury, and change in both morphology and cell surface
markers. E2 suppresses microglial activation, and this
response is regulated by both estrogen receptors.
Microglia, peripheral infiltrating macrophages, and astro-
cytes are the primary source of the iNOS enzyme during
stroke. Activation of iNOS during stroke produces high,
concentrated levels of nitric oxide that promote neuronal
cell death. Many studies have shown that E2 suppresses
iNOS in animal models of neuroinflammation, stroke,
and Alzheimer’s disease, and this response is also regu-
lated by both estrogen receptors.
19,24,25
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critical role in the pathophysiology of human cerebral
ischemia. There is a positive correlation between high
levels of proinflammatory cytokines in serum or cere-
brospinal fluid greater stroke severity. These cytokines
include: interleukin 6 (IL-6), IL-1β, tumor necrosis fac-
tor alpha (TNF-α), and macrophage chemoattractant
protein–1 (MCP-1). Conversely, increased levels of anti-
inflammatory cytokines (eg, IL-10) correlate with dimin-
ished stroke severity and an improved outcome.
Cytokines in the brain perform pleiotropic functions in
inflammation and are synthesized primarily by microglia
and astrocytes, but also can be produced by neurons.
26,27
In several different brain injury paradigms, subcutaneous
E2 generally suppresses proinflammatory cytokines, and
enhances the production anti-inflammatory cytokines.
16,27
Studies from our laboratory have shown that immediate
treatment with E2 following MCAO suppresses brain
levels of the proinflammatory cytokines IL-6 and MCP-
1.
16
Estradiol and neurogenesis
One of the most remarkable discoveries in modern neu-
roscience is that the adult brain continues to generate
new neurons under both normal and neurodegenerative
conditions. We have explored whether E2 stimulates gen-
eration of newborn neurons after stroke. We have found
that low, physiological levels of E2 increase the number
of newborn neurons (Figure 2). Interestingly, both ERα
and ERβ play essential functional roles, and the pres-
ence of both receptor forms is the prerequisite for E2 to
enhance neurogenesis. Although precise roles for each
ER form are yet to be determined, our study clearly
demonstrates that the presence of both receptors is
important in expansion of neuronal populations in the
subventricular zone after ischemic injury.
28
So far, we have not been able to determine whether
these newborn neurons actually differentiate into
mature neurons at this time point, whether they migrate
to the site of injury, and whether they undergo synapse
formation with neighboring neurons. These future stud-
ies will allow us to determine whether this elevated level
of neurogenesis is critical to the recovery of function. 
Importance of timing of estrogen therapy
Recent studies describing the seemingly contradictory
actions of estrogens in stroke injury have led us to
believe that the timing of estrogen therapy relative to the
time of the menopause may be an important factor to
consider. It is important to remember that in the WHI,
the mean age of the subjects was 63 years, and thus, the
majority of subjects were 12 years past the peri-
menopausal transition prior to the initiation of any hor-
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Figure 1. Overview of the brain cell types and neuromodulators influenced
by estrogens. The ability of estrogens to exert trophic and pro-
tective actions depends upon their ability to alter the birth and
death of neurons, synaptogenesis, and neuritogenesis. Estradiol
influences neurons, astrocytes, and microglia through altering
the expression of a broad profile of neurotransmitters and neu-
ropeptides and their receptors, pro- and anti-inflammatory
agents, and factors which influence, birth, survival, growth, and
maturation of neurons.
Figure 2. Estradiol influences the number of newborn neurons. Panel A
shows confocal micrographs of newborn neurons dual-labeled
with bromodeoxyuridine and doublecortin in vehicle and estra-
diol-treated mice following stroke injury. Panel B shows the
mean of groups of 4 to 6 animals in each experimental group
and shows that the differences are statistically significant.
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5,29 We tested the hypothesis that an
extended period of hypoestrogenicity both prevents E2
from protecting the brain against ischemia, and simulta-
neously suppresses its anti-inflammatory actions. We
found that E2 exerts profound neuroprotective action
when administered immediately upon ovariectomy, but
not when administered after 10 weeks of hypoestro-
genicity. This dichotomous action is due to differential
actions that estradiol has when administered immediately
versus when treatment is initiated after a delay (Figure
3). Consistently, E2 treatment given immediately at the
time of ovariectomy attenuated central and peripheral
production of proinflammatory cytokines after ischemic
stroke. In contrast, E2 did not suppress production of
proinflammatory molecules when it was administered 10
weeks postovariectomy.
16These results demonstrate that
a prolonged period of hypoestrogenicity disrupts both
neuroprotective and anti-inflammatory actions of E2.
Our findings may help to explain the results of the WHI
that reported no beneficial effect of ET against stroke
because the majority of the subjects initiated ET after an
extended period of hypoestrogenicity.
Summary
We have summarized recent studies that have increased
our understanding of the complex actions of estrogens
on the brain. These basic science and clinical studies give
us a new appreciation of the breadth of estrogen actions
in the adult brain to maintain function after injury or
during disease. Much more work is necessary before we
fully understand the many ways through which estrogens
exert beneficial actions, but it is clear that estradiol pro-
tects the brain from injury and enhances neurogenesis
by acting to both enhance survival of neurons and stim-
ulate the birth of new neurons, respectively. Estradiol’s
anti-inflammatory actions may underpin both the pro-
tective and reparative effects. We hope that our growing
knowledge of the pleiotropic actions of this hormone
will lead to preventative and restorative therapies for
neurodegenerative conditions, which will, in turn
improve the lives of our aging population.  ❏
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Figure 3. Estradiol protects the brain only if treatment is initiated imme-
diately after hypoestrogenicity is induced. Estradiol decreases
the size of the infarct, induces estrogen receptor (ER) and sup-
presses inflammation only if it is administered immediately after
ovariectomy. We have used ovariectomy to mimic the
menopause. These findings strongly suggest that, if estrogen
therapy (ET) is initiated after several years of postmenopause, as
was the case in the Womens' Health Initiative, that ET will not
be effective in protecting the brain against neurodegeneration.
Estrogen therapy
Early
Brain infarction
ER expression
Inflammation
Overall effect Beneficial Detrimental
Delayed
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Estradiol: una hormona con diversas y 
contradictorias acciones neuroprotectoras
Durante la última década el concepto de que los
estrógenos ejercen importantes acciones neuro-
protectoras ha ganado considerable atención. Hay
numerosos estudios que han proporcionado una
comprensión profunda de las acciones aparente-
mente contradictorias de los estrógenos.
Actualmente se comprende más que nunca que los
efectos de los estrógenos (con y sin progestinas
simultáneas o en secuencia) son diversos y algunas
veces opuestos. Estos efectos dependen del uso de
diferentes compuestos estrogénicos y progestínicos,
de las variadas vías de administración, de las diver-
sas concentraciones, de la secuencia de tratamiento
y de la edad y estado de salud de la mujer que
recibe la terapia hormonal. Durante los últimos
años, se ha alcanzado una mayor comprensión
acerca del impacto de los estrógenos en el sistema
inmune y en la inflamación. Además, se sabe que
los estrógenos no sólo pueden proteger contra la
muerte celular, sino que también pueden estimular
el nacimiento de nuevas neuronas. Se propone que
el concepto de la modulación que tienen los estró-
genos sobre el sistema inmune puede ser el meca-
nismo básico que subyace a su capacidad de pro-
tección contra la neurodegeneración y sus
poderosas acciones neurorregenerativas. Se espera
que esta actualización fomente los enriquecedores
diálogos entre los cientistas básicos y los clínicos
para asegurar que los futuros estudios clínicos con-
sideren muy bien la información que pueda deri-
varse de estudios de ciencia básica. Sólo entonces
se tendrá una mejor comprensión del impacto de
las hormonas en el período menopáusico y post-
menopáusico en la vida de la mujer. 
Œstradiol : une hormone aux actions 
neuroprotectrices diverses et contradictoires
Ces 10 dernières années, l’idée d’une action neuro-
protectrice importante des œstrogènes a retenu par-
ticulièrement l’attention. Les actions apparemment
contradictoires de ces hormones sont nettement
mieux comprises grâce aux nombreuses études cli-
niques. Nous réalisons plus que jamais que leurs
effets (avec ou sans progestatif associé de façon
simultanée ou séquentielle) sont variés et parfois
opposés, dépendant de l’utilisation des différents
composés œstrogéniques ou progestatifs, des diffé-
rents modes d’administration et concentrations, de
la chronologie des traitements, et enfin de l’âge et
de l’état de santé des femmes qui reçoivent le trai-
tement hormonal. Ces dernières années, l’apprécia-
tion de l’impact des œstrogènes sur le système
immunitaire et l’inflammation s’est considérable-
ment étendue. Nous avons appris non seulement
qu’ils protégeaient les cellules de l’apoptose, mais
qu’ils stimulaient également la production de nou-
veaux neurones. Nous postulons dans cet article que
la modulation œstrogénique de l’état immunitaire
pourrait être le mécanisme de base qui sous-tend sa
capacité protectrice contre la neurodégénération et
sa puissante activité neurorégénératrice. Nous espé-
rons que cette mise à jour encouragera un dialogue
plus riche entre des scientifiques cliniciens et fon-
damentalistes pour s’assurer que les études cliniques
futures prendront complètement en compte l’in-
formation provenant de la recherche fondamentale.
C’est seulement alors que nous comprendrons l’im-
pact des hormones sur la période de ménopause et
de post-ménopause dans la vie d’une femme.
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